RESEARCH TRIANGLE PARK, NC--Drug development company Intercardia here is aggressively expanding, with the company's most recent move being to sign a letter of intent to acquire combinatorial chemistry company Transcell Technologies, Monmouth Junction, NJ. Signed in November, the deal calls for Intercardia to pay approximately $15 million in stock for Transcell, which has a $48 million deal with Merck to discover and evaluate two antibacterial compounds.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.